39,202 CVS Health Corporation $CVS Shares Bought by Triasima Portfolio Management inc.

Triasima Portfolio Management inc. raised its stake in CVS Health Corporation (NYSE:CVS) by 119.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 71,917 shares of the pharmacy operator’s stock after buying an additional 39,202 shares during the quarter. Triasima Portfolio Management inc.’s holdings in CVS Health were worth $6,163,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its position in shares of CVS Health by 148.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,419,866 shares of the pharmacy operator’s stock worth $378,738,000 after buying an additional 2,643,571 shares during the last quarter. Ninety One UK Ltd purchased a new stake in CVS Health during the third quarter valued at approximately $222,000. State of Alaska Department of Revenue boosted its stake in CVS Health by 24.0% in the third quarter. State of Alaska Department of Revenue now owns 192,696 shares of the pharmacy operator’s stock valued at $16,512,000 after acquiring an additional 37,259 shares in the last quarter. Turtle Creek Wealth Advisors LLC boosted its stake in CVS Health by 43.8% in the third quarter. Turtle Creek Wealth Advisors LLC now owns 11,209 shares of the pharmacy operator’s stock valued at $960,000 after acquiring an additional 3,414 shares in the last quarter. Finally, WealthPlan Investment Management LLC boosted its stake in CVS Health by 76.0% in the third quarter. WealthPlan Investment Management LLC now owns 3,470 shares of the pharmacy operator’s stock valued at $297,000 after acquiring an additional 1,498 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on CVS shares. Weiss Ratings downgraded CVS Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 9th. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price objective on shares of CVS Health in a report on Wednesday, September 9th. Wells Fargo & Company raised their price objective on CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Robert W. Baird set a $107.00 price objective on CVS Health in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded CVS Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, October 11th. Twenty equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $107.80.

CVS Health Stock Performance

Shares of CVS Health stock opened at $92.45 on Friday. The firm has a market capitalization of $118.25 billion, a P/E ratio of 24.46, a PEG ratio of 0.84 and a beta of 0.60. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The company has a 50 day moving average price of $91.80 and a 200 day moving average price of $93.03. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period last year, the business earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts expect that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be issued a $0.6650 dividend. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
• Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
• Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.